Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

825
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
825
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

605
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
605
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

899
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
899
Diagnosing Acidosis and Alkalosis01:24

Diagnosing Acidosis and Alkalosis

995
Diagnosing acid-base imbalances involves systematically analyzing arterial blood samples, focusing on three key measurements: pH, bicarbonate (HCO3−) concentration, and carbon dioxide partial pressure (PCO2). This analysis follows a four-step process that helps identify the imbalance's underlying cause and nature.
First, the pH level is assessed to determine whether the blood pH is normal (7.35–7.45), low (acidosis), or high (alkalosis).
Next, the PCO2  and...
995
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

141
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
141
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

680
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
680

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistic integration of Fe-MOF and biomass-derived activated carbon for enhanced ciprofloxacin adsorption: experimental insights and DFT-based mechanistic elucidation.

RSC advances·2026
Same author

Acuphagia with sequential ingestion of sharp metallic objects and a magnet, causing intestinal bezoar, perforation, and peritonitis: a case report.

International journal of surgery case reports·2026
Same author

Clinical Outcomes of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Heart Failure: A Real-World Propensity-Matched TriNetX Analysis.

Biomedicines·2026
Same author

Cardiovascular Outcomes with Colchicine in Coronary Artery Disease and HFpEF: A Propensity-Matched TriNetX Analysis.

Journal of cardiovascular development and disease·2026
Same author

Existence of gender bias in clinical dentistry: A cross-sectional study on Perception and experience of dental clinicians at a private dental institute in Lahore.

Pakistan journal of medical sciences·2026
Same author

Harnessing Tolypothrix sp. A-8 for biogenic synthesis of silver oxide nanoparticles (AgONPs) for multifunctional biomedical applications.

Discover nano·2026

Related Experiment Video

Updated: Jan 9, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

563

Indications of Bempedoic Acid.

Muhammad Abdullah1, Noman Khalid2, William H Frishman3

  • 1From the Department of Internal Medicine, HCA Florida Oak Hill Hospital, Brooksville, FL.

Cardiology in Review
|December 8, 2025
PubMed
Summary

Bempedoic acid effectively lowers low-density lipoprotein cholesterol (LDL-C), reducing cardiovascular events, especially in statin-intolerant patients. It offers a valuable option for achieving lipid goals through combination therapy.

Keywords:
atherosclerotic cardiovascular diseasebempedoic acidlow-density lipoprotein cholesterolmajor adverse cardiovascular event

More Related Videos

Author Spotlight: Integrating 2D-HPLC-MS and Molecular Networking in Natural Medicine Analysis
07:50

Author Spotlight: Integrating 2D-HPLC-MS and Molecular Networking in Natural Medicine Analysis

Published on: December 8, 2023

1.1K

Related Experiment Videos

Last Updated: Jan 9, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

563
Author Spotlight: Integrating 2D-HPLC-MS and Molecular Networking in Natural Medicine Analysis
07:50

Author Spotlight: Integrating 2D-HPLC-MS and Molecular Networking in Natural Medicine Analysis

Published on: December 8, 2023

1.1K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease is a leading cause of mortality, driven by elevated low-density lipoprotein cholesterol (LDL-C).
  • Lowering LDL-C is crucial for reducing atherosclerotic cardiovascular disease events.
  • Current guidelines recommend early and sustained LDL-C reduction.

Purpose of the Study:

  • To review the evidence and guideline positioning of bempedoic acid in lipid management.
  • To highlight bempedoic acid's role in contemporary strategies for LDL-C reduction.

Main Methods:

  • Synthesis of current evidence from randomized controlled trials.
  • Review of regulatory approvals and guideline recommendations.
  • Analysis of bempedoic acid's efficacy and safety profile.

Main Results:

  • Bempedoic acid, an adenosine triphosphate-citrate lyase inhibitor, achieves 15-20% LDL-C reduction as monotherapy.
  • Combination therapy with ezetimibe can yield up to 40% LDL-C reduction.
  • Bempedoic acid demonstrates cardiovascular event reduction in statin-intolerant patients with reduced myotoxicity risk.

Conclusions:

  • Bempedoic acid is approved for patients intolerant to statins or inadequately controlled.
  • It supports contemporary lipid management emphasizing earlier combination therapy and lower LDL-C thresholds.
  • The drug facilitates long-term maintenance of treatment goals for cardiovascular risk reduction.